These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8411550)

  • 1. Examining product risk in context. Market withdrawal of zomepirac as a case study.
    Ross-Degnan D; Soumerai SB; Fortess EE; Gurwitz JH
    JAMA; 1993 Oct; 270(16):1937-42. PubMed ID: 8411550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Use of Prescription Nonsteroidal Anti-inflammatory Medications Before vs After Implementation of a Florida Law Restricting Opioid Prescribing for Acute Pain.
    Keshwani S; Grande I; Maguire M; Goodin A; Vouri SM; Hincapie-Castillo JM
    JAMA Netw Open; 2021 Jun; 4(6):e2113383. PubMed ID: 34115125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining product risk in context: the case of zomepirac.
    Musa BU
    JAMA; 1994 Oct; 272(16):1252. PubMed ID: 7802819
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of prescription pattern of analgesic use among ambulatory elderly in South-Western Nigeria.
    Akande-Sholabi W; Agha PC; Olowookere OO; Adebusoye LA
    Ann Afr Med; 2020; 19(2):131-136. PubMed ID: 32499470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector.
    Meuwesen WP; du Plessis JM; Burger JR; Lubbe MS; Cockeran M
    Int J Clin Pharm; 2016 Aug; 38(4):863-9. PubMed ID: 27091130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: a randomized controlled trial.
    Ray WA; Stein CM; Byrd V; Shorr R; Pichert JW; Gideon P; Arnold K; Brandt KD; Pincus T; Griffin MR
    Med Care; 2001 May; 39(5):425-35. PubMed ID: 11317091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing early prescribers of newly marketed drugs in Canada: a population-based study.
    Kozyrskyj A; Raymond C; Racher A
    Eur J Clin Pharmacol; 2007 Jun; 63(6):597-604. PubMed ID: 17380324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analgesic prescribing for musculoskeletal complaints in the ambulatory care setting after the introduction and withdrawal of cyclooxygenase-2 inhibitors.
    Wilson RD
    Arch Phys Med Rehabil; 2009 Jul; 90(7):1147-51. PubMed ID: 19577028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining product risk in context: the case of zomepirac.
    Spielberg TE
    JAMA; 1994 Oct; 272(16):1252; author reply 1252-3. PubMed ID: 7933364
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of an academic detailing intervention in primary care on the prescribing of non-steroidal anti-inflammatory drugs.
    Langaas HC; Hurley E; Dyrkorn R; Spigset O
    Eur J Clin Pharmacol; 2019 Apr; 75(4):577-586. PubMed ID: 30596208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postsurgical pain: zomepirac sodium, propoxyphene/-acetaminophen combination, and placebo.
    Honig S; Murray KA
    J Clin Pharmacol; 1981 Oct; 21(10):443-8. PubMed ID: 7031101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prescription drug monitoring programs and pill mill laws on high-risk opioid prescribers: A comparative interrupted time series analysis.
    Chang HY; Lyapustina T; Rutkow L; Daubresse M; Richey M; Faul M; Stuart EA; Alexander GC
    Drug Alcohol Depend; 2016 Aug; 165():1-8. PubMed ID: 27264166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical company influence on nonsteroidal anti-inflammatory drug prescribing behaviors.
    Naik AD; Woofter AL; Skinner JM; Abraham NS
    Am J Manag Care; 2009 Apr; 15(4):e9-15. PubMed ID: 19341315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing Associated with High-Risk Opioid Exposures Among Non-cancer Chronic Users of Opioid Analgesics: a Social Network Analysis.
    Hinami K; Ray MJ; Doshi K; Torres M; Aks S; Shannon JJ; Trick WE
    J Gen Intern Med; 2019 Nov; 34(11):2443-2450. PubMed ID: 31420823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study.
    Strom BL; Berlin JA; Kinman JL; Spitz PW; Hennessy S; Feldman H; Kimmel S; Carson JL
    JAMA; 1996 Feb; 275(5):376-82. PubMed ID: 8569017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provider Perspectives on Topical Analgesics.
    Smith MA; Cho K; Rodgers P
    J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):44-48. PubMed ID: 29787324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a complex intervention to improve primary care prescribing: a phase IV segmented regression interrupted time series analysis.
    MacBride-Stewart S; Marwick C; Houston N; Watt I; Patton A; Guthrie B
    Br J Gen Pract; 2017 May; 67(658):e352-e360. PubMed ID: 28347986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs.
    Strom BL; Carson JL; Morse ML; West SL; Soper KA
    Arthritis Rheum; 1987 Oct; 30(10):1142-8. PubMed ID: 3314878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.